Literature DB >> 19997042

Cytochrome b5 and NADH cytochrome b5 reductase: genotype-phenotype correlations for hydroxylamine reduction.

James C Sacco1, Lauren A Trepanier.   

Abstract

OBJECTIVES: NADH cytochrome b5 reductase (b5R) and cytochrome b5 (b5) catalyze the reduction of sulfamethoxazole hydroxylamine (SMX-HA), which can contribute to sulfonamide hypersensitivity, to the parent drug sulfamethoxazole. Variability in hydroxylamine reduction could thus play a role in adverse drug reactions. The aim of this study was to characterize variability in SMX-HA reduction in 111 human livers, and investigate its association with single nucleotide polymorphisms (SNPs) in b5 and b5R cDNA.
METHODS: Liver microsomes were assayed for SMX-HA reduction activity, and b5 and b5R expression was semiquantified by immunoblotting. The coding regions of the b5 (CYB5A) and b5R (CYB5R3) genes were resequenced.
RESULTS: Hepatic SMX-HA reduction displayed a 19-fold range of individual variability (0.06-1.11 nmol/min/mg protein), and a 17-fold range in efficiency (Vmax/Km) among outliers. SMX-HA reduction was positively correlated with b5 and b5R protein content (P<0.0001, r=0.42; P=0.01, r=0.23, respectively), and expression of both proteins correlated with one another (P<0.0001; r=0.74). A novel cSNP in CYB5A (S5A) was associated with very low activity and protein expression. Two novel CYB5R3 SNPs, R59H and R297H, displayed atypical SMX-HA reduction kinetics and decreased SMX-HA reduction efficiency.
CONCLUSION: These studies indicate that although novel cSNPs in CYB5A and CYB5R3 are associated with significantly altered protein expression and/or hydroxylamine reduction activities, these low-frequency cSNPs seem to only minimally impact overall observed phenotypic variability. Work is underway to characterize polymorphisms in other regions of these genes to further account for individual variability in hydroxylamine reduction.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19997042      PMCID: PMC2905818          DOI: 10.1097/FPC.0b013e3283343296

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN: 1744-6872            Impact factor:   2.089


  42 in total

1.  Sequence and structure-based prediction of eukaryotic protein phosphorylation sites.

Authors:  N Blom; S Gammeltoft; S Brunak
Journal:  J Mol Biol       Date:  1999-12-17       Impact factor: 5.469

2.  Variation is the spice of life.

Authors:  L Kruglyak; D A Nickerson
Journal:  Nat Genet       Date:  2001-03       Impact factor: 38.330

3.  Nomenclature for the description of human sequence variations.

Authors:  J T den Dunnen; S E Antonarakis
Journal:  Hum Genet       Date:  2001-07       Impact factor: 4.132

4.  Human non-synonymous SNPs: server and survey.

Authors:  Vasily Ramensky; Peer Bork; Shamil Sunyaev
Journal:  Nucleic Acids Res       Date:  2002-09-01       Impact factor: 16.971

5.  Covalent binding of the nitroso metabolite of sulfamethoxazole is important in induction of drug-specific T-cell responses in vivo.

Authors:  Linling Cheng; Benjamin J Stewart; Qiang You; Dennis R Petersen; Joseph A Ware; Joseph R Piccotti; Thomas T Kawabata; Cynthia Ju
Journal:  Mol Pharmacol       Date:  2008-03-11       Impact factor: 4.436

Review 6.  Epidemiology, pathology, and genetics of prostate cancer among African Americans compared with other ethnicities.

Authors:  Heinric Williams; Isaac J Powell
Journal:  Methods Mol Biol       Date:  2009

Review 7.  Recessive congenital methaemoglobinaemia: cytochrome b(5) reductase deficiency.

Authors:  Melanie J Percy; Terry R Lappin
Journal:  Br J Haematol       Date:  2008-03-03       Impact factor: 6.998

8.  Discovery and characterization of a cytochrome b5 variant in humans with impaired hydroxylamine reduction capacity.

Authors:  Joseph R Kurian; Brett J Longlais; Lauren A Trepanier
Journal:  Pharmacogenet Genomics       Date:  2007-08       Impact factor: 2.089

9.  Familial idiopathic methemoglobinemia revisited: original cases reveal 2 novel mutations in NADH-cytochrome b5 reductase.

Authors:  Melanie J Percy; Matthew J S Gillespie; Geraldine Savage; Anne E Hughes; Mary Frances McMullin; Terry R J Lappin
Journal:  Blood       Date:  2002-07-05       Impact factor: 22.113

10.  Recent trends in breast cancer among younger women in the United States.

Authors:  Louise A Brinton; Mark E Sherman; J Daniel Carreon; William F Anderson
Journal:  J Natl Cancer Inst       Date:  2008-11-11       Impact factor: 13.506

View more
  21 in total

1.  Membrane-bound CYB5R3 is a common effector of nutritional and oxidative stress response through FOXO3a and Nrf2.

Authors:  Emilio Siendones; Sara SantaCruz-Calvo; Alejandro Martín-Montalvo; María V Cascajo; Julia Ariza; Guillermo López-Lluch; José M Villalba; Cécile Acquaviva-Bourdain; Emmanuel Roze; Michel Bernier; Rafael de Cabo; Plácido Navas
Journal:  Antioxid Redox Signal       Date:  2014-02-28       Impact factor: 8.401

2.  Structure Guided Chemical Modifications of Propylthiouracil Reveal Novel Small Molecule Inhibitors of Cytochrome b5 Reductase 3 That Increase Nitric Oxide Bioavailability.

Authors:  Md Mizanur Rahaman; Fabio G Reinders; David Koes; Anh T Nguyen; Stephanie M Mutchler; Courtney Sparacino-Watkins; Roger A Alvarez; Megan P Miller; Dongmei Cheng; Bill B Chen; Edwin K Jackson; Carlos J Camacho; Adam C Straub
Journal:  J Biol Chem       Date:  2015-05-22       Impact factor: 5.157

3.  Evaluation of polymorphisms in the sulfonamide detoxification genes CYB5A and CYB5R3 in dogs with sulfonamide hypersensitivity.

Authors:  J Funk-Keenan; J Sacco; Y Y Amos Wong; S Rasmussen; A Motsinger-Reif; L A Trepanier
Journal:  J Vet Intern Med       Date:  2012-07-21       Impact factor: 3.333

4.  Individual variability in the detoxification of carcinogenic arylhydroxylamines in human breast.

Authors:  Keelia Rhoads; James C Sacco; Nicholas Drescher; Amos Wong; Lauren A Trepanier
Journal:  Toxicol Sci       Date:  2011-03-29       Impact factor: 4.849

5.  Loss of smooth muscle CYB5R3 amplifies angiotensin II-induced hypertension by increasing sGC heme oxidation.

Authors:  Brittany G Durgin; Scott A Hahn; Heidi M Schmidt; Megan P Miller; Neha Hafeez; Ilka Mathar; Daniel Freitag; Peter Sandner; Adam C Straub
Journal:  JCI Insight       Date:  2019-10-03

6.  Drug antigenicity, immunogenicity, and costimulatory signaling: evidence for formation of a functional antigen through immune cell metabolism.

Authors:  Ayman Elsheikh; Sidonie N Lavergne; J Luis Castrejon; John Farrell; Haiyi Wang; Jean Sathish; Werner J Pichler; B Kevin Park; Dean J Naisbitt
Journal:  J Immunol       Date:  2010-10-27       Impact factor: 5.422

7.  Dapsone-associated methemoglobinemia in a patient with slow NAT2*5B haplotype and impaired cytochrome b5 reductase activity.

Authors:  Mahmoud Abouraya; James C Sacco; Kristie Hayes; Sajeve Thomas; Craig S Kitchens; Lauren A Trepanier
Journal:  J Clin Pharmacol       Date:  2012-02       Impact factor: 3.126

8.  Cytochrome b5 Reductase 3 Modulates Soluble Guanylate Cyclase Redox State and cGMP Signaling.

Authors:  Mizanur M Rahaman; Anh T Nguyen; Megan P Miller; Scott A Hahn; Courtney Sparacino-Watkins; Soma Jobbagy; Nolan T Carew; Nadiezhda Cantu-Medellin; Katherine C Wood; Catherine J Baty; Francisco J Schopfer; Eric E Kelley; Mark T Gladwin; Emil Martin; Adam C Straub
Journal:  Circ Res       Date:  2017-06-05       Impact factor: 17.367

9.  Polymorphisms in the carcinogen detoxification genes CYB5A and CYB5R3 and breast cancer risk in African American women.

Authors:  Kristina L Blanke; James C Sacco; Robert C Millikan; Andrew F Olshan; Jingchun Luo; Lauren A Trepanier
Journal:  Cancer Causes Control       Date:  2014-09-16       Impact factor: 2.506

10.  Genome-wide interaction study of smoking and bladder cancer risk.

Authors:  Jonine D Figueroa; Summer S Han; Montserrat Garcia-Closas; Dalsu Baris; Eric J Jacobs; Manolis Kogevinas; Molly Schwenn; Nuria Malats; Alison Johnson; Mark P Purdue; Neil Caporaso; Maria Teresa Landi; Ludmila Prokunina-Olsson; Zhaoming Wang; Amy Hutchinson; Laurie Burdette; William Wheeler; Paolo Vineis; Afshan Siddiq; Victoria K Cortessis; Charles Kooperberg; Olivier Cussenot; Simone Benhamou; Jennifer Prescott; Stefano Porru; H Bas Bueno-de-Mesquita; Dimitrios Trichopoulos; Börje Ljungberg; Françoise Clavel-Chapelon; Elisabete Weiderpass; Vittorio Krogh; Miren Dorronsoro; Ruth Travis; Anne Tjønneland; Paul Brenan; Jenny Chang-Claude; Elio Riboli; David Conti; Manuela Gago-Dominguez; Mariana C Stern; Malcolm C Pike; David Van Den Berg; Jian-Min Yuan; Chancellor Hohensee; Rebecca Rodabough; Geraldine Cancel-Tassin; Morgan Roupret; Eva Comperat; Constance Chen; Immaculata De Vivo; Edward Giovannucci; David J Hunter; Peter Kraft; Sara Lindstrom; Angela Carta; Sofia Pavanello; Cecilia Arici; Giuseppe Mastrangelo; Margaret R Karagas; Alan Schned; Karla R Armenti; G M Monawar Hosain; Chris A Haiman; Joseph F Fraumeni; Stephen J Chanock; Nilanjan Chatterjee; Nathaniel Rothman; Debra T Silverman
Journal:  Carcinogenesis       Date:  2014-03-24       Impact factor: 4.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.